Guo Radiochemistry and Molecular Imaging Lab
Sidebar
About
Guo lab focuses on the theranostic applications of radiopharmaceuticals. For diagnosis, we focus on the development of novel non-invasive PET (positron emission tomography) imaging biomarkers for early diagnosis and management of cancer and infection. For therapy, we focus on developing novel targeted radiotherapy and radioimmunotherapy for melanoma, pancreatic, lung, and pediatric brain tumors. The lab also develops novel fusion antibodies for targeted immunotherapy of cancer.
Key Research Areas
Radiochemistry
Radiopharmaceutical
Molecular Imaging
Positron Emission Tomography (PET) and CT imaging
Targeted Radionuclide Therapy
Radiotherapy
Radioimmunotherapy
Imaging Cancer Inflammation
Multifunctional fusion antibody
Tumor immune microenvironment
Current Projects
- Development of novel PET agents for imaging the pancreatic cancer immune microenvironment.
- Development of targeted radioimmunotherapy for pancreatic cancer.
- Development of multi-functional radioimmunotherapeutics for pediatric high-grade glioma.
- Development of ImmunoPET platform for imaging the tumor immune microenvironment of pediatric brain tumor.
- Utilize synthetic biology for molecular imaging of cancer.
Team
Haixun Guo, PhD
PI, assistant professor
502-852-5577
Dheetchana Sasikumar, MS
Research Assistant III
dheetchana.sasikumar@louisville.edu
502-852-1517
Recent Publications
- Caleb Bridgwater, Anne Geller, Xiaoling Hu, Joe Burlison, Huang-Ge Zhang, Jun Yan, Haixun Guo. (2020). 89Zr-labeled anti-PD-L1 antibody fragment for evaluating in vivo PD-L1 levels in melanoma mouse mode. Cancer Biother Radiopharm. 2020 Oct;35(8):549-557 PMID: 32315549.
- Anne E Geller; Rejeena Shrestha; Haixun Guo; Chuanlin Ding; Matthew R Woeste; Kalina Andreeva; Julia H. Chariker; Xiaoling Hu; Mingqian Zhou; David Tieri; Corey T Watson; Robert Mitchell; Huang-ge Zhang; Yan Li; Robert C.G. Martin; Eric C Rouchk; Jun Yan. (2022) The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat. Commun. 9;13(1):759. PMID: 35140221